| "Cancer defeated": not if, but when--introducing the Biology of Neoplasia series |
| SA Cannistra |
|
JCO Nov 1 1997: 3297–3298.
[PDF]
|
 |
| Chemotherapy for advanced gastric cancer: where do we stand? |
| CS Fuchs |
|
JCO Nov 1 1997: 3299–3300.
[PDF]
|
|
|
Role of the retinoblastoma protein in the pathogenesis of human cancer |
| |
WR Sellers and WG Kaelin, Jr |
| |
JCO Nov 1 1997: 3301–3312.
[Abstract]
[PDF]
|
|
|
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer |
| |
S Cascinu, R Labianca, P Alessandroni, M Marcellini, RR Silva, G Pancera, E Testa, G Martignoni, S Barni, L Frontini, A Zaniboni, G Luporini, R Cellerino, and G Catalano |
| |
JCO Nov 1 1997: 3313–3319.
[Abstract]
[PDF]
|
|
|
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer |
| |
RM Goldberg, AK Hatfield, M Kahn, DJ Sargent, JA Knost, MJ O'Connell, JE Krook, JA Maillard, M Wiesenfeld, PL Schaefer, MT Tirona, and CG Moertel |
| |
JCO Nov 1 1997: 3320–3329.
[Abstract]
[PDF]
|
|
|
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon- alpha2a in pediatric patients with refractory cancer |
| |
PC Adamson, G Reaman, JZ Finklestein, J Feusner, SL Berg, SM Blaney, M O'Brien, RF Murphy, and FM Balis |
| |
JCO Nov 1 1997: 3330–3337.
[Abstract]
[PDF]
|
|
|
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease |
| |
DL Longo, E Glatstein, PL Duffey, RC Young, DC Ihde, AW Bastian, WH Wilson, RE Wittes, ES Jaffe, SM Hubbard, and VT DeVita, Jr |
| |
JCO Nov 1 1997: 3338–3346.
[Abstract]
[PDF]
|
|
|
Successful pregnancy after allogeneic bone marrow transplant with embryos isolated before transplant |
| |
JH Lipton, M Virro, and H Solow |
| |
JCO Nov 1 1997: 3347–3349.
[Abstract]
[PDF]
|
|
|
Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies |
| |
C Ippoliti, R Champlin, N Bugazia, D Przepiorka, J Neumann, S Giralt, I Khouri, and J Gajewski |
| |
JCO Nov 1 1997: 3350–3354.
[Abstract]
[PDF]
|
|
|
CD30 ligand in lymphoma patients with CD30+ tumors |
| |
A Younes, U Consoli, V Snell, K Clodi, KO Kliche, JL Palmer, HJ Gruss, R Armitage, EK Thomas, F Cabanillas, and M Andreeff |
| |
JCO Nov 1 1997: 3355–3362.
[Abstract]
[PDF]
|
|
|
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer |
| |
ML Disis, SM Pupa, JR Gralow, R Dittadi, S Menard, and MA Cheever |
| |
JCO Nov 1 1997: 3363–3367.
[Abstract]
[PDF]
|
|
|
Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin |
| |
C Isaacs, NJ Robert, FA Bailey, MW Schuster, B Overmoyer, M Graham, B Cai, KJ Beach, JW Loewy, and JA Kaye |
| |
JCO Nov 1 1997: 3368–3377.
[Abstract]
[PDF]
|
|
|
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study |
| |
LH Maurer, JE Herndon, 2nd, DR Hollis, J Aisner, RW Carey, AT Skarin, MC Perry, WL Eaton, LL Zacharski, S Hammond, and MR Green |
| |
JCO Nov 1 1997: 3378–3387.
[Abstract]
[PDF]
|
|
|
Lung cancer metastatic cells detected in blood by reverse transcriptase- polymerase chain reaction and dot-blot analysis |
| |
G Castaldo, R Tomaiuolo, A Sanduzzi, ML Bocchino, A Ponticiello, E Barra, D Vitale, F Bariffi, L Sacchetti, and F Salvatore |
| |
JCO Nov 1 1997: 3388–3393.
[Abstract]
[PDF]
|
|
|
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer |
| |
WM Stadler, T Kuzel, B Roth, D Raghavan, and FA Dorr |
| |
JCO Nov 1 1997: 3394–3398.
[Abstract]
[PDF]
|
|
|
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion |
| |
RP Edwards, W Gooding, BC Lembersky, K Colonello, R Hammond, C Paradise, CD Kowal, AJ Kunschner, M Baldisseri, JM Kirkwood, and RB Herberman |
| |
JCO Nov 1 1997: 3399–3407.
[Abstract]
[PDF]
|
|
|
Patterns of care for women with ovarian cancer in the United States |
| |
KA Munoz, LC Harlan, and EL Trimble |
| |
JCO Nov 1 1997: 3408–3415.
[Abstract]
[PDF]
|
|
| Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy. Adopted on July 21, 1997 by the American Society of Clinical Oncology |
|
|
JCO Nov 1 1997: 3416–3417.
[PDF]
|
|
| Pancreatic panniculitis |
| R Brown, R Buckley, and M Kelley |
|
JCO Nov 1 1997: 3418–3419.
[PDF]
|
|
| Intensity of surveillance after breast conservation |
| I Kunkler, G Kerr, and W Jack |
|
JCO Nov 1 1997: 3420a.
[PDF]
|
|
| Salvage treatment of ovarian cancer |
| FM Muggia |
|
JCO Nov 1 1997: 3420b–3421.
[PDF]
|
|
